Dr Pei Ding
MA MBBChir (Cantab) FRACP PHD, Medical Oncologist
English, Mandarin, Cantonese, Malay
Lung cancer, mesothelioma, oesophageal cancer, gastric cancer, pancreatic cancer, biliary cancer and colorectal cancer
Cooking, exploring the outdoors
Special clinical interest in lung cancer, mesothelioma, oesophageal cancer, gastric cancer, pancreatic cancer, biliary cancer and colorectal cancer.
After completing her medical school at University of Cambridge and physician training, Pei moved to Australia to undertake further physician training and medical oncology training in 2011. She developed an interest in translational research and undertook PhD research at Liverpool Hospital and the Ingham Institute, where she was awarded a postgraduate PhD scholarship and Lung Foundation research grant for her research investigating role of liquid biopsy in advanced lung cancer.
Pei is appointed as a staff specialist for medical oncology at Nepean Blue Mountain Local Health District since 2019, with subspecialties of interest being lung and gastro-intestinal cancers. Pei is passionate about precision medicine and has considerable experience in chemotherapy, targeted therapies and immunotherapies for the treatment of lung cancer and gastrointestinal cancers.
Pei is actively involved in clinical research and clinical trials. She is passionate about teaching and supervision of junior medical doctors as well as medical oncology trainees and PhD students. She has received multiple awards and publications (listed below).
In her spare time, Pei enjoys cooking and spending time exploring outdoors with her husband and sons.
- ALTG Young Investigator Award 2019
- Australian Postgraduate Award Scholarship 2013
- Lung Foundation Grant-in-aid in Lung Cancer Research 2016
- Astra Zeneca Independent Research Grant 2017
- Thomas Ashworth Symposium ‘Most Outstanding Presentation’ Prize
- Cambridge Commonwealth Trust Bursary
- William Harvey Prize for clinical exam, Cambridge University
- Scholar for Christ’s College, Cambridge University
PHD research focused on the understanding of how liquid biopsy with circulating tumour cells and circulating tumour DNA could be used to monitor for disease response and resistance to treatment for patients with advanced lung cancer.
- Royal Australasian College of Physicians (RACP)
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- Thoracic Oncology Group Australia (TOGA)
- Lung Foundation
- The Australasian Gastro-Intestinal Trials Group (AGITG)
- Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. Ding PN, Roberts TL, Chua W, Becker TM, Caixeiro N, de Souza P, et al. Translational Lung Cancer Research. 2021;10(4):1623-34
- Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutationis in patients with advanced lung cancer treated with subsequent-line osimertinib. Ding PN, Becker, T, Bray V, Chua W, Ma Y, Xu B, Lynch D, de Souza P, Roberts T Thoracic Cancer 2019 Oct; 10 (10): 1879-1884
- The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study. Ding PN, Becker TM, Bray VJ, Chua W, Ma YF, Lynch D, Po J, Luk AWS, Caixeiro N, de Souza P, Roberts TL. Lung Cancer. 2019 Aug;134:187-193
- Droplet digital PCR-based detection of EGFR mutations in advanced lung cancer patient liquid biopsies: A comparison of circulating tumor DNA extraction kits Ding PN, Ma YF, Roberts TL, Chua W, Bray VJ, Lynch D, Burke D, de Souza P, Becker TM. Journal of Mol Biomarkers and Diagnostics. 2018; 9(397)
- Clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer in South Western Sydney Local Health District. Ding PN, Roberts TL, Chua W, Becker TM, Descallar J, Yip PY, Bray VJ. Intern Med J. 2017 Dec; 47 (12): 1405-1411.
- Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK. J Thorac Oncol. 12:633-643, 2017
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after treatment with EGFR Tyrosine Kinase Inhibitors vs Chemotherapy in EGFR-mutant Lung Cancer: A Meta-Analysis Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. J Clin Oncol. 2015 Jun 10; 33(17): 1958-1965